Abstract
The purpose of this study was to evaluate the effect of alpha-IFN maintenance treatment after autologous stem cell transplantation (ASCT) for multiple myeloma in a retrospective registry analysis. 473 patients with multiple myeloma who received IFN maintenance treatment ASCT were compared with 419 patients who did not receive IFN-treatment. Patients who were evaluable for response and in complete or partial remission at 6 months after ASCT were eligible, after excluding patients with graft failure. Cox proportional hazards assumptions were checked and handled by stratification. The prognostic variables unevenly distributed between the two groups were statistically corrected for in the Cox analysis. 391 patients reached complete remission (CR) after ASCT (203 in the IFN group and 188 in the no-IFN group) and 501 were in partial remission (PR, IFN 270, no-IFN 231). Overall survival (OS) and progression-free survival (PFS) were significantly better in the IFN-group (OS, 78 vs 47 months, P = 0.007, and PFS, 29 vs 20 months, P = 0.006, respectively). The difference in OS and PFS was most strongly pronounced in the PR patients. 209 patients have died (IFN, 84; no-IFN, 125). Progressive myeloma was the cause of death in 94% of the IFN-treated patients and in 83% of the no-IFN group (P = NS). Thus, IFN maintenance treatment after ASCT was associated with better OS and PFS. Treatment seemed to be most beneficial in patients who did not achieve CR. The difference in median survival was as long as 2.5 years, and although part of this difference is attributable to differences in other prognostic factors, it might justify possible differences in quality-of-life due to adverse effects of interferon treatment. Bone Marrow Transplantation (2001) 27, 511–515.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Björkstrand B, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma – a retrospective case-matched study from the European Group for Blood and Marrow Transplantation Blood 1996 88: 4711–4718
Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med 1996 335: 91–97
Mellstedt H, Aahre A, Björkholm M et al. Interferon therapy in myelomatosis Lancet 1979 1: 245–247
Mandelli F, Rees JKH, Gorin NC, Prentice HG . Post-remission treatment in acute myeloid leukemia: chemotherapy or autologous or allogeneic bone marrow transplantation Haematologica 1990 75: 203–211
Cooper MR, Dear K, McIntyre R et al. A randomized clinical trial comparing melphalan/prednisolone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study J Clin Oncol 1993 11: 155–160
Österborg A, Björkholm M, Björeman M et al. Natural interferon-α in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden Blood 1993 81: 1428–1434
Salmon SE, Crowley JJ, Grogan TM et al. Combination chemotherapy, glucocorticoids and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study J Clin Oncol 1994 12: 2405–2414
Ludwig H, Cohen AM, Polliack A et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicentre randomized trials and summary of other studies Ann Oncol 1995 6: 467–476
Hjorth M, Westin J, Dahl IMS et al. Interferon-α2b added to melphalan-prednisolone for initial and maintenance therapy in multiple myeloma: a randomized, controlled trial Ann Intern Med 1996 124: 212–222
Bladé J, San Miguel JF, Escudero ML et al. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology) Leukemia 1998 12: 1144–1148
Byrne JL, Carter GI, Bienz N et al. Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma Bone Marrow Transplant 1998 22: 639–644
Attal M, Huguet F, Schlaifer D et al. Intensive combined therapy for previously untreated aggressive myeloma Blood 1992 79: 1130–1136
Harousseau J-L, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma Blood 1995 85: 3077–3085
Alegre A, Díaz-Mediavilla J, San-Miguel J et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish registry Bone Marrow Transplant 1998 21: 133–140
Cunningham D, Powles R, Malpas J et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results Br J Haematol 1998 102: 495–502
Mandelli F, Avvisati G, Amadori S et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy N Engl J Med 1990 322: 1430–1434
Browman GE, Rubin S, Walker L et al. Interferon α-2b (IFN) maintenance therapy prolongs progression free and overall survival in plasma cell myeloma (PCM) Proc Am Soc Clin Oncol 1994 13: 408
Westin J, Rödjer S, Turesson I et al. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study Br J Haematol 1995 89: 561–568
Peest D, Deicher H, Coldwey R et al. A comparison of polychemotherapy and melphalan prednisolone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group Eur J Cancer 1995 31: 146–151
Drayson MT, Chapman CE, Dunn JA et al. MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults Br J Haematol 1998 101: 195–202
Ludwig H, Fritz E, Neuda J, Durie BG . Patient preferences for interferon alfa in multiple myeloma J Clin Oncol 1997 15: 1672–1679
Zee B, Cole B, Li T et al. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma J Clin Oncol 1998 16: 2834–2839
Wisløff F . Quality of life and patients’ perception in interferon treated myeloma patients VII International Multiple Myeloma Workshop Stockholm 1999 100
Author information
Authors and Affiliations
Additional information
on behalf of the EBMT Myeloma Subcommittee
Rights and permissions
About this article
Cite this article
Björkstrand, B., Svensson, H., Goldschmidt, H. et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 27, 511–515 (2001). https://doi.org/10.1038/sj.bmt.1702826
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702826
Keywords
This article is cited by
-
Post-Transplant Maintenance Treatment Options in Multiple Myeloma
Oncology and Therapy (2021)
-
Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma
Bone Marrow Transplantation (2017)
-
Fortschritte in der Behandlung von Patienten mit multiplem Myelom
Der Onkologe (2010)
-
Cure of multiple myeloma – more hype, less reality
Bone Marrow Transplantation (2006)